<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-40406" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Biohazard Levels</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bayot</surname>
            <given-names>Marlon L.</given-names>
          </name>
          <aff>Adventist University of the Philippines-College of Medicine; Coach MLB Consulting</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>King</surname>
            <given-names>Kevin C.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marlon Bayot declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kevin King declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-40406.s1" sec-type="Definition/Introduction">
        <title>Definition/Introduction</title>
        <p content-type="pubmed-excerpt">Biohazard levels, more commonly referred to as &#x0201c;biological safety levels&#x0201d; or &#x0201c;biosafety levels,&#x0201d; are classifications of safety precautions necessary to be applied in the clinical microbiology laboratory depending on specific pathogens handled when performing laboratory procedures. Developed by the Centers for Disease Control and Prevention (CDC), this principle allows medical laboratory scientists and other lab personnel to identify and limit any biological hazards and further&#x000a0;reduce&#x000a0;the risk in the laboratory. Biohazard levels, on the other hand, also support the principle of biosecurity, which aims at preventing the use of microorganisms as harmful biological agents.</p>
        <p>Four classifications of biosafety levels (BSLs) exist. Each level contains specific recommendations for a clinical microbiology laboratory focusing on laboratory practices, safety equipment, and facility construction. As each level progresses, it includes additional biosafety considerations from the previous level. For example, BSL-2 has kept the components of BSL-1 with further requirements, and the same applies to BSL-3 (BSL-2 with additional requirements) and BSL-4 (BSL-3 with additional requirements). The complexity of each level aligns with infectivity, disease severity, the microorganisms&#x02019; ability for transmission (including exposure routes), and the nature of the laboratory work to be performed.</p>
        <p>Implementing biosafety and biosecurity in the laboratory can initially present an additional burden to laboratory staff and managers. However, they should not ignore the relevance of applying&#x000a0;biosafety principles in the workplace.<xref ref-type="bibr" rid="article-40406.r1">[1]</xref></p>
      </sec>
      <sec id="article-40406.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>Laboratory-associated infections continue to become sources of diseases to the laboratory workforce. This is&#x000a0;due to failing to implement fundamental control measures in the laboratory. This stems from the most effective control: "<italic toggle="yes">elimination,"</italic>&#x000a0;followed by "<italic toggle="yes">substitution,"</italic>&#x000a0;"<italic toggle="yes">engineering controls,"</italic>&#x000a0;"<italic toggle="yes">administrative,"</italic>&#x000a0;and "<italic toggle="yes">personal protective equipment"</italic> (eg, respirator use) as the least effective.<xref ref-type="bibr" rid="article-40406.r2">[2]</xref><xref ref-type="bibr" rid="article-40406.r3">[3]</xref></p>
        <p><bold>Biosafety level 1 (BSL-1)</bold> controls microorganisms unusually known to cause disease with "minimal hazards" to the laboratory and the community. A recent study involves the selection of a BSL-1 bacteriophage surrogate to assess the efficacy of a chlorine-based surface disinfectant for Ebola outbreaks. This study recommends the collaboration of BSL-4 and non-BSL-4 facilities to assist in selecting and researching better surrogates, which can be more effective in BSL-4 conditions.<xref ref-type="bibr" rid="article-40406.r4">[4]</xref></p>
        <p><bold>Biosafety level 2 (BSL-2)</bold> controls microorganisms generating "moderate hazards" to the laboratory and the community. In other parts of the world, there are still no guidelines for validating and certifying biosafety laboratories<xref ref-type="bibr" rid="article-40406.r2">[2]</xref>. The year 2017 saw the identification and analysis of issues regarding biosafety implementation in BSL-2 and BSL-3. There is a need to make clear distinctions between certification and validation of clinical and microbiological laboratories. The need for careful implementation must be first recognized.<xref ref-type="bibr" rid="article-40406.r5">[5]</xref></p>
        <p><bold>Biosafety level 3 (BSL-3)</bold> includes the control of infectious agents, which can cause both "serious hazards" and a potentially lethal condition to the laboratory and community via the respiratory transmission of the organism. A typical example of an organism under this classification is&#x000a0;<italic toggle="yes">Mycobacterium tuberculosis</italic>, the bacterial agent responsible for tuberculosis. There have been challenges for program and tuberculosis (TB) laboratory managers in implementing the specific considerations for this level, particularly in resource-limited and TB, high-burden settings because there is insufficient biosafety expertise available to conduct individualized risk assessments for TB laboratories. Applying the biosafety level classification in BSL-3 requirements may not practically and adequately match the specific precautions relevant to the laboratories performing TB-related tests and procedures. To solve this problem, TB laboratories adopted a risk-assessment approach instead of applying the concept of BSL-3 (which is a risk-group approach). Any TB laboratory (a clinical, medical, or public health laboratory carrying out TB diagnostic tests) can classify as low risk, moderate risk, or high TB risk based on the amount of aerosol generated during the conduct of a particular laboratory procedure. Countries with TB, still a significant public health concern, have adopted these guidelines.<xref ref-type="bibr" rid="article-40406.r6">[6]</xref><xref ref-type="bibr" rid="article-40406.r7">[7]</xref><xref ref-type="bibr" rid="article-40406.r8">[8]</xref></p>
        <p><bold>Biosafety level 4 (BSL-4)</bold> is the highest and "most complex" biohazard level, involving a relatively few clinical microbiology laboratories. A high transmission via aerosol makes the pathogens more dangerous for the laboratory workforce and the surrounding community. Marburg and Ebola viruses fall into this risk group. Stakeholders and international experts attended European conferences to revisit the issues that emerged for BSL-4 implementation. They seek opportunities to use BSL-4 in public health, diagnostics, and research regarding its sustainability, improvement of existing training designs and curricula, and strong collaboration to address biosafety and biosecurity. An integrated partnership of human, veterinary, and military laboratories with BSL-4 facilities is necessary to unify its approach to developing laboratory biosafety standards. The participation of BSL-4 in outbreaks can be substantial to attain more effective outbreak management.<xref ref-type="bibr" rid="article-40406.r9">[9]</xref></p>
      </sec>
      <sec id="article-40406.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Risk-group classification of required biosafety precautions is ideally a logical approach to minimize laboratory-acquired infections. However, while each laboratory can easily identify and meet the special considerations required, the&#x000a0;practicality of the actual day-to-day situation of the laboratory workflow is still more important. Strict adherence to these biohazard levels can benefit some facilities that can comply. In a similar case previously described for TB laboratories, a risk-based approach is more applicable&#x000a0;so that safety precautions can be "tailor-fit" to the activities of each clinical laboratory. Further studies are still essential to make this a reality on a global scale.<xref ref-type="bibr" rid="article-40406.r10">[10]</xref><xref ref-type="bibr" rid="article-40406.r8">[8]</xref></p>
        <p>
<bold>Biohazard Level and Significance&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Biohazard Level 1</italic> usually includes viruses and bacteria like <italic toggle="yes">Escherichia coli, chickenpox,</italic>&#x000a0;and many non-infectious&#x000a0;bacteria. The level of precaution at this level is minimal and usually involves wearing a face mask and no close contact.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Biohazard Level 2</italic> usually involves microorganisms responsible for mild infections in humans. These organisms are often difficult to contract via aerosolized particles, such as hepatitis A, B,&#x000a0;and C, Lyme disease, <italic toggle="yes">Salmonella</italic>, measles, mumps, HIV, and dengue. Laboratory personnel can perform diagnostic tests on the specimens but must wear gloves, facial protection,&#x000a0;and a gown.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Biohazard Level 3</italic> includes microorganisms that can be fatal to humans but for which vaccines and other treatments are available. In addition to&#x000a0;<italic toggle="yes">Mycobacterium tuberculosis</italic>, this grouping also includes anthrax, many types of viral encephalitis, hantavirus, Rift Valley fever, SARS-CoV-2 (COVID-19), malaria, Rocky Mountain spotted&#x000a0;fever and yellow&#x000a0;fever.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Biohazard Level 4</italic> usually includes dangerous&#x000a0;viruses like Ebola, Marburg virus, Lassa fever, Bolivian hemorrhagic fever, and many other hemorrhagic viruses found in the tropics. Only specific persons can work with these&#x000a0;viruses, requiring them to wear a positive pressure personnel suit with a segregated air supply. No treatment is available for these viruses, and extreme isolation precautions are mandatory. The CDC has many recommendations on how to manage these viruses. There are no bacteria in this group.</p>
          </list-item>
        </list>
        <p>Knowledge of biohazard levels must not be limited to laboratory professionals. All healthcare workers need to be aware of the categories of biohazard levels because they can impact every patient. For instance, signs and symbols should always be posted&#x000a0;on medical floors when dealing with a high-level biohazard.</p>
      </sec>
      <sec id="article-40406.s4">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=40406&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=40406">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/40406/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=40406">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-40406.s5">
        <title>References</title>
        <ref id="article-40406.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coelho</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a D&#x000ed;ez</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Biological Risks and Laboratory-Acquired Infections: A Reality That Cannot be Ignored in Health Biotechnology.</article-title>
            <source>Front Bioeng Biotechnol</source>
            <year>2015</year>
            <volume>3</volume>
            <fpage>56</fpage>
            <pub-id pub-id-type="pmid">25973418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-40406.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mourya</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Majumdar</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Chauhan</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Katoch</surname>
                <given-names>VM</given-names>
              </name>
            </person-group>
            <article-title>Establishment of Biosafety Level-3 (BSL-3) laboratory: important criteria to consider while designing, constructing, commissioning &#x00026; operating the facility in Indian setting.</article-title>
            <source>Indian J Med Res</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>140</volume>
            <issue>2</issue>
            <fpage>171</fpage>
            <page-range>171-83</page-range>
            <pub-id pub-id-type="pmid">25297350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-40406.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Callaway</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Biosafety concerns for labs in the developing world.</article-title>
            <source>Nature</source>
            <year>2012</year>
            <month>May</month>
            <day>22</day>
            <volume>485</volume>
            <issue>7399</issue>
            <fpage>425</fpage>
            <pub-id pub-id-type="pmid">22622543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-40406.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallandat</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lantagne</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Selection of a Biosafety Level 1 (BSL-1) surrogate to evaluate surface disinfection efficacy in Ebola outbreaks: Comparison of four bacteriophages.</article-title>
            <source>PLoS One</source>
            <year>2017</year>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>e0177943</fpage>
            <pub-id pub-id-type="pmid">28531182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-40406.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mourya</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Khare</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Certification &#x00026; validation of biosafety level-2 &#x00026; biosafety level-3 laboratories in Indian settings &#x00026; common issues.</article-title>
            <source>Indian J Med Res</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>146</volume>
            <issue>4</issue>
            <fpage>459</fpage>
            <page-range>459-467</page-range>
            <pub-id pub-id-type="pmid">29434059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-40406.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <source>Tuberculosis Laboratory Biosafety Manual</source>
            <publisher-name>World Health Organization</publisher-name>
            <publisher-loc>Geneva</publisher-loc>
            <year>2012</year>
            <pub-id pub-id-type="pmid">24404640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-40406.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parsons</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Somosk&#x000f6;vi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gutierrez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Paramasivan</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Abimiku</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Spector</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roscigno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nkengasong</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>314</fpage>
            <page-range>314-50</page-range>
            <pub-id pub-id-type="pmid">21482728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-40406.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Soolingen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wisselink</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Lumb</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Anthony</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van der Zanden</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gilpin</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Practical biosafety in the tuberculosis laboratory: containment at the source is what truly counts.</article-title>
            <source>Int J Tuberc Lung Dis</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>8</issue>
            <fpage>885</fpage>
            <page-range>885-9</page-range>
            <pub-id pub-id-type="pmid">25199000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-40406.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nisii</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Castilletti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Raoul</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hewson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gopal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eickmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gunther</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mirazimi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koivula</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Feldmann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Di Caro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Capobianchi</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Ippolito</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Biosafety Level-4 laboratories in Europe: opportunities for public health, diagnostics, and research.</article-title>
            <source>PLoS Pathog</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>e1003105</fpage>
            <pub-id pub-id-type="pmid">23349630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-40406.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kojima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Booth</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Summermatter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heisz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blacksell</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>McKinney</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Risk-based reboot for global lab biosafety.</article-title>
            <source>Science</source>
            <year>2018</year>
            <month>Apr</month>
            <day>20</day>
            <volume>360</volume>
            <issue>6386</issue>
            <fpage>260</fpage>
            <page-range>260-262</page-range>
            <pub-id pub-id-type="pmid">29674576</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
